Abstract:Inhibitor of apoptosis-stimulating protein of p53 (iASPP), encoded by PPP1R13L gene, is often overexpressed in human cancers. From the PPP1R13L gene, at least two isoforms, iASPP-L and iASPP-SV, are produced through alternative splicing. However, the role of these isoforms in glioma is still elusive. In this study, we examined the expression of iASPP-SV in astrocytic glioma tissues with different grades and normal human cerebral tissues. The result showed a higher messenger RNA (mRNA) expression level of iASPP-SV in astrocytic glioma patients with World Health Organization (WHO) grade II to IV in comparison to the normal controls. Additionally, mRNA expression level of iASPP-SV was gradually increased with the raise of the grade in glioma. High mRNA expression level of iASPP-SV was significantly associated with malignant WHO grades (P<0.001). The protein expression level of iASPP-SV was consistent with the mRNA expression level. The Kaplan-Meier analysis revealed that high iASPP-SV mRNA expression significantly affected overall survival and progression-free survival (both P<0.001). Furthermore, multivariate analysis indicated that the mRNA expression of iASPP-SV was an independent prognostic marker in glioma (P<0.001). To further explore the role of iASPP-SV in glioma, U87 cells were transfected with iASPP-SV by lentivirus and then treated with temozolomide (TMZ). Overexpression of iASPP-SV promoted the cell viability and downregulated the expression of proapoptosis genes (Bax, Puma, p21, and Noxa) to inhibit apoptosis induced by TMZ. Our study provides the first evidence that high iASPP-SV expression may be a novel prognostic factor and therapeutic target for glioma.

siRNA-mediated down-regulation of iASPP promotes apoptosis induced by etoposide and daunorubicin in leukemia cells expressing wild-type p53.

The expression of iASPP in acute leukemias.

High iASPP (PPP1R13L) expression is an independent predictor of adverse clinical outcome in acute myeloid leukemia (AML)

Oncogene Iaspp Enhances Self‐renewal of Hematopoietic Stem Cells and Facilitates Their Resistance to Chemotherapy and Irradiation

Sertad1 Antagonizes Iaspp Function by Hindering Its Entrance into Nuclei to Interact with P53 in Leukemic Cells

Cisplatin Induces Apoptosis of Hepatocellular Carcinoma LM3 Cells Via Down-Regulation of XIAP.

FHL2 Interacts with Iaspp and Impacts the Biological Functions of Leukemia Cells.

iASPP-SV, an Important iASPP isoform, participated in breast tumorigenesis/progression

Evaluation of apoptosis stimulating protein of TP53-1 (ASPP1/ PPP1R13B ) to predict therapy resistance and overall survival in acute myeloid leukemia (AML)

Iaspp is Over-Expressed in Human Non-Small Cell Lung Cancer and Regulates the Proliferation of Lung Cancer Cells Through a P53 Associated Pathway

Iaspp Overexpression is Associated with Clinical Outcome in Spinal Chordoma and Influences Cellular Proliferation, Invasion, and Sensitivity to Cisplatin in Vitro.

Iaspp Oncoprotein Potentates the Proliferation Peculiarity of Cells Derived from Murine Bone Marrow

Iasppsv Antagonizes Apoptosis Induced by Chemotherapeutic Agents in MCF-7 Cells and Mouse Thymocytes

Enhanced Expressions of FHL2 and Iaspp Predict Poor Prognosis in Acute Myeloid Leukemia.

RNA Interference Targeting Mutant P53 Inhibits Growth and Induces Apoptosis in DU145 Human Prostate Cancer Cells

Targeting Transcription Factor SALL4 in Acute Myeloid Leukemia by Interrupting Its Interaction with an Epigenetic Complex.

Reactivating p53 functions by suppressing its novel inhibitor iASPP: a potential therapeutic opportunity in p53 wild-type tumors

Identification of a Novel Isoform of Iaspp and Its Interaction with P53

Overexpression of Iaspp-Sv in Glioma is Associated with Poor Prognosis by Promoting Cell Viability and Antagonizing Apoptosis.

iASPP suppression mediates terminal UPR and improves BRAF-inhibitor sensitivity of colon cancers

Role of Signal Regulatory Protein α in Arsenic Trioxide-induced Promyelocytic Leukemia Cell Apoptosis